Dr Martine Keenan Discusses Drug Targets for Chagas Disease Research

We’re excited to invite a global audience to join our CSO Dr Martine Keenan‘s webinar on “The role of CYP51 inhibitors in Chagas disease research”, which is part of a series to support the Global Health drug discovery community during the ongoing Covid-19 crisis.

 

Martine’s talk covers the suitability of sterol 14α-demethylase, or CYP51, as a drug target for inhibiting growth and replication of T. cruzi to treat Chagas disease. This was a great hope to the field over a decade ago, but whilst research programs targeting this mechanism have not delivered a new chemical entity to the clinic, many useful lessons have been learnt along the way to advance the field.

 

This webinar describes research and learnings from T. cruzi medicinal chemistry programs undertaken by Drugs for Neglected Diseases initiative – DNDi‘s Chagas disease Consortium that shape our approach to Chagas disease drug discovery efforts today, including the ideal profile of screening hits, identifying T. cruzi CYP51 pharmacophores, and a screening cascade for compound triage.

 

In case you missed it, Dr Martine Keenan‘s webinar is now available to view online at a time that suits you: https://lnkd.in/gJBp9Ge.

Leave a Comment